open access
Vol 14, No 5 (2018)
Other materials agreed with the Editors
Published online: 2019-02-15
Get Citation
Current literature review
Maciej Kawecki1
DOI: 10.5603/OCP.2018.0038
·
Oncol Clin Pract 2018;14(5):290-294.
Affiliations- Department of Oncology and Radiotherapy, Maria Sklodowska-Curie Institute of Oncology, Warsaw
open access
Vol 14, No 5 (2018)
CURRENT LITERATURE REVIEW
Published online: 2019-02-15
Abstract
xxx
Abstract
xxx
Get Citation
About this articleTitle
Current literature review
Journal
Issue
Article type
Other materials agreed with the Editors
Pages
290-294
Published online
2019-02-15
Page views
1375
Article views/downloads
428
DOI
10.5603/OCP.2018.0038
Bibliographic record
Oncol Clin Pract 2018;14(5):290-294.
Authors
Maciej Kawecki
References (5)- Horn L, Mansfield AS, Szczęsna A, et al. IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018 [Epub ahead of print].
- Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379(1): 54–63.
- Smith M, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. New England Journal of Medicine. 2018; 378(15): 1408–1418.
- Hussain M, Fizazi K, Saad F, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018; 378(26): 2465–2474.
- Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018; 379(8): 753–763.